title: Itraconazole in the treatment of onychomycosis: a double-blind comparison with miconazole.
abstract: BACKGROUND
  In recent years, itraconazole pulse therapy for onychomycosis has been developed [three 1-week pulses with itraconazole 400 (2 x 200) mg daily every month]. This has proved an effective and safe regimen which requires only 50% of the medication used for continuous dosing schedules. Parallel to the development of the new dosage schedule, additional studies were conducted to further document the safety and efficacy of itraconazole 200 mg once daily for 3 months to treat onychomycosis.
  
  
  OBJECTIVE
  To compare the safety of itraconazole 200 mg once daily for 3 months, with or without itraconazole 200 mg once weekly for a further 3 months, with that of miconazole cream twice daily for 6 months, in the treatment of onychomycosis. Treatment efficacy was compared as a secondary objective.
  
  
  METHODS
  In this multicenter, double-blind study, patients were randomized to receive itraconazole 200 mg once daily for 3 months followed by either itraconazole 200 mg once weekly for 3 months (ITR-ITR group, n = 599) or oral placebo once weekly for 3 months (ITR-PLAC group, n = 613), or to receive miconazole cream twice daily for 6 months (MIC-MIC group, n = 396). The primary variable was elevation of alanine amino-transferase (ALT) concentration above 50 U/I.
  
  
  RESULTS
  Overall incidence of elevation of ALT concentration above 50 U/I, adverse events and rate of withdrawal because of adverse events were low and similar in the three treatment groups. Efficacy was significantly greater in the ITR groups than the MIC-MIC group.
  
  
  CONCLUSIONS
  Itraconazole and miconazole were well tolerated and had no significant effect on liver function, but itraconazole was significantly more effective.
authors.affiliation: Department of Dermatology, Wuppertal Hospitals, University of Witten/Herdecke, Beerse, Belgium.
authors.forename: E
authors.initials: E
authors.lastname: Haneke
authors.forename: M
authors.initials: M
authors.lastname: Tajerbashi
authors.forename: P
authors.initials: P
authors.lastname: De Doncker
authors.forename: A
authors.initials: A
authors.lastname: Heremans
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005533:Foot Dermatoses / Q000188:drug therapy; D005858:Germany; D006229:Hand Dermatoses / Q000188:drug therapy; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use*; D008297:Male; D008825:Miconazole / Q000627:therapeutic use*; D008875:Middle Aged; D014009:Onychomycosis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D017964:Itraconazole; D008825:Miconazole